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Postexposure Prophylaxis Against Varicella-Zoster
Virus Infection Among Recipients of Hematopoietic
Stem Cell Transplant: Unresolved Issues
David M. Weinstock, MD; Michael Boeckh, MD; Farid Boulad, MD; Janet A. Eagan, RN; Victoria J. Fraser, MD; 
David K. Henderson, MD; Trish M. Perl, MD, MSc; Deborah Yokoe, MD, MPH; Kent A. Sepkowitz, MD
Recent guidelines for the prevention of opportunistic infec-
tions have addressed a variety of issues germane to recipients of
hematopoietic stem cell transplant. However, there are several
issues regarding postexposure prophylaxis against varicella-zoster
virus that remain unresolved. We address these questions and
offer several consensus recommendations (Infect Control Hosp
Epidemiol 2004;25:603-608).
Varicella-zoster virus (VZV) causes significant mor-
bidity in recipients of hematopoietic stem cell transplant.
Recent studies have reported VZV disease (ie, either vari-
cella or zoster) in 10% to 67% of recipients of autologous
and allogeneic hematopoietic stem cell transplants.1-19
Recommendations for the prevention of opportunistic
infections among recipients of hematopoietic stem cell
transplant were jointly published in 2000 by the Centers
for Disease Control and Prevention, the Infectious
Diseases Society of America, and the American Society for
Blood and Bone Marrow Transplantation.20,21 Multiple
guidelines for the prevention and treatment of VZV among
recipients of hematopoietic stem cell transplant are includ-
ed in the recommendations (Table 1). However, six com-
mon clinical issues were not specifically addressed. We
discuss these issues, highlight areas of continued contro-
versy, and make consensus recommendations when possi-
ble.
WHAT CONSTITUTES A VZV EXPOSURE
AMONG RECIPIENTS OF HEMATOPOIETIC
STEM CELL TRANSPLANT?
VZV can be transmitted to recipients of hematopoi-
etic stem cell transplant through either direct contact
with or inhalation of respiratory secretions from an indi-
vidual with VZV disease.22 The risk of acquiring VZV is
directly proportional to the duration and intensity of con-
tact and inversely proportional to the exposed individ-
ual’s immunity to VZV. Varicella develops in approxi-
mately 90% of immunocompetent, susceptible household
contacts who receive no prophylaxis after exposure to
varicella and 25% after exposure to zoster.23,24 The risk of
VZV transmission after exposure to varicella decreases to
less than 20% following brief contact (eg, with playmates
or exposure in the hospital).22 Importantly, nosocomial
transmission of VZV to seronegative individuals who had
no known contact with the index case-patient has
occurred.25-28 The roles of air ventilation systems and
intermediaries who may have harbored clinical or sub-
clinical infection (eg, hospital staff) are poorly under-
stood. 
Because of these reports and the significant poten-
tial for complications from VZV among recipients of
hematopoietic stem cell transplant, an inclusive definition
for “exposure” seems appropriate. However, the literature
does not support an absolute definition for exposure and
the authors did not reach a consensus. Some authors con-
sider any contact with an individual with varicella or
zoster (ie, other than a single dermatome that was com-
pletely covered) to be an exposure. This includes all
Drs. Weinstock and Sepkowitz and Ms. Eagan are from the Department of Medicine and Dr. Boulad is from the Department of Pediatrics,
Memorial Sloan-Kettering Cancer Center, New York, New York. Dr. Yokoe is from Brigham and Women’s Hospital and Harvard Medical School, Boston,
Massachusetts. Dr. Henderson is from the Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland. Dr. Boeckh is from
the Fred Hutchinson Cancer Research Center and the Unviersity of Washington, Seattle, Washington. Dr. Fraser is from the Washington University School
of Medicine, St. Louis, Missouri. Dr. Perl is from the Department of Hospital Epidemiology and Infection Control, The Johns Hopkins Hospital,
Baltimore, Maryland.
Address reprint requests to David M. Weinstock, MD, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box
109, New York, NY 10021.
Supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) grant no. K24 AI52239-01(KAS);
National Cancer Institute, NIH grant no. CA18029 (MB); and National Cancer Institute, NIH grant no. CA009512 (DMW).
ABSTRACT
Infections in Immunocompromised Patients
EDITED BY KENT A. SEPKOWITZ, MD
604 INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY July 2004
patients who spent time on the same inpatient unit or out-
patient clinic as an individual with VZV disease who was
not appropriately isolated. Other authors think that this
definition is overly inclusive and relegates too many
patients with minimal or no risk of acquiring VZV to
unnecessary treatment and isolation. As with many
pathogens of concern to infection control practitioners,
the institutional definitions for VZV exposure were fre-
quently affected by the presence or absence of nosocomi-
al transmission within recent memory.
ARE VZV-SEROPOSITIVE RECIPIENTS OF
HEMATOPOIETIC STEM CELL TRANSPLANT
SUSCEPTIBLE TO VZV REINFECTION (IE,
SECOND ACUTE INFECTION)? 
The conventional wisdom is that the risk of VZV rein-
fection among immunocompetent hosts is negligible.22,29 In
contrast, at least 57 immunocompromised patients with
possible reinfection have been described (Table 2). In a
study of postexposure varicella-zoster immune globulin
(VZIG) among immunocompromised children with no clin-
ical history of varicella, an astounding 28% with detectable
VZV antibodies prior to exposure developed clinically
apparent VZV infection.35 At least 5 recipients of hematopoi-
etic stem cell transplant have developed possible VZV rein-
fections (M. Boeckh, MD, personal communication, April
2003; F. Boulad, MD, personal communication, June
2003).10 Most of the possible reinfections were mild and
manifested as an atypical, maculopapular rash without vis-
ceral involvement. In many cases, the diagnosis of reinfec-
tion was based on an appropriate temporal relationship
between exposure and the onset of symptoms and support-
ed by serologic evidence of immunity prior to reinfection.
The patients frequently had no clinical history of varicella
and VZV antibody titers prior to reinfection were low,
potentially resulting from passive immunization through
transfused blood products, immune globulin, or both.20
Together, these reports suggest a low, but not insignificant,
rate of reinfection in this group of patients.
WHAT IS THE ROLE OF VZIG FOR
POSTEXPOSURE PROPHYLAXIS AMONG
VZV-SEROPOSITIVE RECIPIENTS OF
HEMATOPOIETIC STEM CELL TRANSPLANT?
Given that seropositive recipients of hematopoietic
stem cell transplant may be at risk for reinfection, estab-
lished interventions must be considered after an exposure.
The arguments for and against postexposure VZIG for VZV-
seropositive recipients of hematopoietic stem cell transplant
are listed in Table 3. There is no evidence that passive anti-
body prophylaxis with VZIG augments preexisting humoral
response or reduces the risk of VZV reactivation among
VZV-seropositive recipients of hematopoietic stem cell trans-
plant.2,42 In addition, a dose–response relationship does not
clearly exist between VZIG dose and the risk of developing
varicella. In a randomized trial, doubling the dose of VZIG
had no effect on the likelihood of developing clinically appar-
ent VZV infection (adjusted risk ratio, 1.00).35
A particularly compelling point in favor of VZIG
administration is the potential for false-positive VZV anti-
body results. Commercially available VZV antibody tests
vary markedly in sensitivity and specificity43 and have not
been evaluated specifically for recipients of hematopoietic
stem cell transplant. As discussed, VZV-naive patients
may passively acquire detectable levels of VZV antibody
from transfused blood products including immune globu-
lin.20 Many laboratories report VZV antibody results as
only “positive” or “negative,” preventing any distinction
between low and high positive titers. Finally, rapid turn-
around of reliable VZV antibody results is not available at
all centers, limiting the practitioner’s ability to make expe-
dient decisions on the need for postexposure VZIG. 
Recipients of hematopoietic stem cell transplant who
are exposed to VZV should undergo antibody testing as soon
as possible after exposure. Despite the potential for false-pos-
itive antibody results, the authors do not routinely recom-
mend VZIG for recipients of hematopoietic stem cell trans-
plant who are VZV seropositive. The low risk of reinfection,
lack of evidence for a VZIG dose–response relationship, lim-
ited efficacy of VZIG, and availability of alternative prophy-
laxis all argue against the use of VZIG for these patients. If
the VZV serostatus is unknown (eg, in settings where rapid
turnaround of VZV antibody results is not available), the
authors recommend that VZIG be administered. Although
TABLE 1
SUMMARY OF MAJOR RECOMMENDATIONS FOR THE PREVENTION
OF INFECTION WITH VARICELLA-ZOSTER VIRUS AS OUTLINED IN
THE GUIDELINES FROM THE CENTERS FOR DISEASE CONTROL
AND PREVENTION, INFECTIOUS DISEASES SOCIETY OF AMERICA,
AND AMERICAN SOCIETY FOR BLOOD AND BONE MARROW
TRANSPLANTATION
Type of Prevention Rating* 
Testing of recipient IgG serostatus AIII 
Counseling about the seriousness of wild-type VZV AII
infection in HSCT recipients and strategies
to prevent exposure†
Vaccination of family members and close household AII 
contacts who are seronegative or have no history
of VZV† 
Respiratory and contact isolation of HSCT recipients AII 
with VZV
Respiratory isolation of seronegative, susceptible AI
HSCT recipients exposed to wild-type VZV†
VZIG within 96 hours for VZV-seronegative recipients AII
following an exposure with wild-type VZV†
Exclusion of HSCT recipients < 24 months EIII
after transplant from receiving VZV vaccine
HSCT = hematopoietic stem cell transplant; VZV = varicella-zoster virus; VZIG = varicella-
zoster immune globulin.
*Rating system follows the scheme developed by the Infectious Diseases Society of America
and the U.S. Public Health Service for the human immunodeficiency virus opportunistic infec-
tion guidelines (Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for
infectious diseases. Clin Infect Dis 1994;18:421.).
†The same recommendations were also made for the VZV vaccine (with BIII rating).  
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this approach uses an expensive resource, prevention of
VZV disease remains a high priority for transplant centers
and the consequences of infection may be substantial.
WHAT IS THE ROLE OF ACYCLOVIR AND
OTHER ANTIHERPETICS FOR VZV
POSTEXPOSURE PROPHYLAXIS AMONG
RECIPIENTS OF HEMATOPOIETIC STEM
CELL TRANSPLANT?
Unfortunately, VZIG appears to be only partially effec-
tive at preventing VZV disease. In studies of VZIG prophy-
laxis, 25% to 45% of treated contacts (including immunocom-
petent individuals) developed clinically apparent varicel-
la.35,44-46
In contrast, acyclovir has demonstrated reasonable
efficacy as prophylaxis for susceptible individuals exposed
to VZV. In one nonrandomized study, varicella developed in
16% of seronegative immunocompetent children treated
with acyclovir during the second week after exposure 
compared with 100% of untreated controls.47 No data are
available on acyclovir as postexposure prophylaxis for
recipients of hematopoietic stem cell transplant. However,
extensive clinical experience indicates that acyclovir and
valacyclovir are highly effective at preventing VZV reacti-
vation in transplant recipients.48-54 In a meta-analysis of
1,574 patients after solid organ transplantation, the risk of
herpes zoster was reduced 94% among patients adminis-
tered any dose of acyclovir or valacyclovir.48 Comparable
TABLE 2




Study No. of Appropriate Laboratory
Study Period Cases Location Incubation Confirmation Description
Feldhoff et al.30 1968–1979 3 Minneapolis, MN Yes Serology in 1 case Pediatric renal transplant recipients
Schimpff et al.31 1969–1971 7 Baltimore, MD 4 of 7 None All cases of “atypical disseminated varicella”
among patients with prior varicella at a can-
cer hospital
Gershon et al.32 1975–1982 8 United States 4 of 8 Serology by mul- Three normal adults, 4 patients with leu-
tiple methods, kemia, and 1 patient with lupus. One 
VZV DNA anal- patient with leukemia developed reinfec-
ysis in 1 case, tion from wild-type VZV 10 months after
cell-mediated im- receiving VZV vaccine.
munity in 2 cases
Morens et al.33 1975–1982 8 Bethesda, MD 7 of 8 Serology in some Eight of 22 cases of VZV during an outbreak
cases among cancer patients
Pallett and 1982 3 England Yes None Outbreak among elderly nursing home
Nichols34 residents
Zaia et al.35 1983 16 United States Yes Serology Immunocompromised children with no
history of varicella and exposed to a sib-
ling with VZV enrolled in a study of vari-
cella immune globulin
Talbot et al.36 1984 1 Philadelphia, PA Yes Serology Nurse without a history of varicella exposed
to a patient with zoster
Husstedt et al.37 1984 1 Germany Unknown Serology Pregnant woman
Ljungman et al.10 1986 3 Sweden Yes None Pediatric bone marrow transplant recipients
McNamara et al.38 1987 1 Milwaukee, WI Yes Serology Renal transplant recipient receiving azath-
ioprine and prednisone
Junker et al.39 1988 7 Denmark Yes None Outbreak among 6 immunocompromised
patients with lymphoproliferative disease
and 1 immunocompromised individual all
reporting childhood varicella
Marczynska40 1989 1 Poland Unknown None Child with acute lymphocytic leukemia
Schoub et al.41 1992 3 South Africa Yes Serology Outbreak among elderly nursing home
residents
VZV = varicella-zoster virus.
*Cases of zoster that occurred after exposure to an index case with zoster or varicella are not included.
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efficacy has been reported in several trials of acyclovir after
hematopoietic stem cell transplant.49-54
The authors recommend that postexposure prophy-
laxis with valacyclovir or acyclovir be considered in addi-
tion to VZIG for all VZV-seronegative recipients of
hematopoietic stem cell transplant. VZV-seropositive recip-
ients of hematopoietic stem cell transplant should also
receive valacyclovir or acyclovir if it has been less than 6
months since an autologous hematopoietic stem cell trans-
plant, it has been less than 12 months since an allogeneic
hematopoietic stem cell transplant, if they are receiving
immunosuppressive therapy, if they have active graft-ver-
sus-host disease, or if they are otherwise immunodeficient
(eg, CD4 count < 200/uL, recent opportunistic infection).
The one exception is seropositive patients who have previ-
ously experienced an episode of VZV disease after
hematopoietic stem cell transplant. These patients appear
to be at no risk for VZV reinfection.20,22
Some authors argued that all recipients of
hematopoietic stem cell transplant who are not immuno-
competent (ie, eligible to receive a live vaccination such as
measles) should receive valacyclovir or acyclovir after VZV
exposure, based on the limited toxicity and cost of these
agents. In addition, the brief duration of therapy is highly
unlikely to induce resistance among VZV. 
No standard doses of acyclovir or valacyclovir have
been clearly justified for postexposure prophylaxis. Based
on institutional experiences and extrapolation from the
treatment of VZV disease, the authors recommend 1 g of
valacyclovir orally three times daily if greater than 40 kg,
or 500 mg orally three times daily if less than 40 kg. An
alternative is 600 mg/m2 of acyclovir four times daily from
days 3 to 22 after exposure. Valacyclovir is not recom-
mended for children younger than 12 years. All VZV-
seronegative (or unknown) recipients should also receive
VZIG within 96 hours after exposure. Because VZIG can
prolong the incubation period of VZV,20,44 valacyclovir (or
acyclovir) should be administered between days 3 and 28
after exposure in patients who also receive VZIG. Patients
who are receiving prophylactic acyclovir or valacyclovir at
lower doses should receive the higher dose during the
period 3 to 22 days (or 3 to 28 days if VZIG was adminis-
tered) after VZV exposure. Patients receiving standard
induction or maintenance doses of ganciclovir, foscarnet,
or cidofovir do not require a change in therapy after VZV
exposure, as these agents are active against VZV.
WHAT TREATMENT IS APPROPRIATE FOR
SUSCEPTIBLE HOUSEHOLD AND OTHER
CLOSE CONTACTS WHO ARE EXPOSED TO
VZV? 
Considering the inordinately high risk of transmis-
sion from household and other close contacts, we recom-
mend an aggressive treatment strategy to avoid VZV dis-
ease among this group. If a VZV-susceptible household or
close contact is exposed to VZV, the contact should receive
VZV vaccination. In a study of immunocompetent children
vaccinated within 3 days of exposure, the protective effica-
cy of VZV vaccine as postexposure prophylaxis was approx-
imately 90%.55 If ineligible for vaccine, the exposed contact
should receive the combination of VZIG and either valacyl-
covir or acyclovir. Because VZIG appears to be significant-
ly less effective at preventing VZV disease than does vacci-
nation, individuals treated with VZIG should also be
offered valacyclovir or acyclovir until day 28 after exposure
(as described earlier) to further reduce both their personal
risk and the risk of transmitting VZV to the recipient of
hematopoietic stem cell transplant. Contact between the
exposed individual and the recipient of hematopoietic stem
cell transplant should be minimized to whatever extent
possible between days 10 and 21 (or 10 and 28 if VZIG was
administered) after exposure. 
ARE CANCER PATIENTS OTHER THAN
THOSE RECEIVING HEMATOPOIETIC STEM
CELL TRANSPLANT AT RISK FOR VZV
REINFECTION?
Prophylaxis after VZV exposure is not routinely rec-
ommended in cancer patients who have not received
hematopoietic stem cell transplant and are VZV seroposi-
tive or report a history of VZV disease. However, most
reported cases of reinfection occurred among patients with
hematologic malignancies who had not undergone
hematopoietic stem cell transplant. In addition, the advent
of new high-dose regimens and chemotherapies (eg, flu-
darabine, alemtuzumab, temozolomide, or high-dose alky-
lating agents) that can induce profound and prolonged
T-cell immunodeficiency has raised concern over the sus-
TABLE 3
ARGUMENTS FOR AND AGAINST THE ADMINISTRATION OF
VARICELLA-ZOSTER IMMUNE GLOBULIN TO VARICELLA-ZOSTER
VIRUS–SEROPOSITIVE RECIPIENTS OF HEMATOPOIETIC STEM CELL
TRANSPLANT EXPOSED TO VARICELLA
For
Theoretical potential for supplementing immunity against VZV
Previous reports of varicella in VZV-seropositive patients
Low incidence of adverse effects associated with VZIG administra-
tion
Only a single dose of VZIG required
Prevents undertreatment of patients with false-positive antibody 
results
Obviates the need for rapid VZV antibody turnaround
Healthcare provider peace of mind
Against
Cost
Paucity of reports of varicella in VZV-seropositive patients
Lack of proven efficacy in VZV IgG–seropositive patients
Potential for adverse effects and discomfort associated with VZIG 
administration (ie, primum non nocere)
Extends the potential VZV incubation period to 28 days after expo-
sure
VZV = varicella-zoster virus; VZIG = varicella-zoster immune globulin.
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ceptibility of some cancer patients to VZV reinfection.
Reactivation of latent herpes viruses can occur after treat-
ment with agents such as fludarabine or alemtuzumab.56,57
However, no cases of VZV reinfection have been reported.
Among these patients, the authors recommend reserving
postexposure prophylaxis against VZV reinfection for those
who (1) are currently receiving highly immunosuppressive
therapy, (2) have a profound T-cell defect, or (3) previously
experienced a significant opportunistic infection caused by
a pathogen associated with cellular immunodeficiency (eg,
Pneumocystis carinii pneumonia or cytomegalovirus reacti-
vation). Further data are clearly needed to establish formal
guidelines for these patients.
DISCUSSION
The guidelines20 of the Centers for Disease Control
and Prevention, Infectious Diseases Society of America,
and American Society for Blood and Bone Marrow
Transplantation for prevention of opportunistic infections
in recipients of hematopoietic stem cell transplant address
many important issues facing transplant and infectious
disease physicians who care for these patients. Infection
control measures, including counseling, vaccination of
close contacts, and early isolation of potential cases of
VZV disease, are the primary mechanisms of preventing
VZV exposures. However, exposures will continue to
occur as VZV disease remains a common event in the pop-
ulation. Despite the potential for severe consequences,
prophylactic regimens to prevent VZV infection among
recipients of hematopoietic stem cell transplant are con-
troversial and vary widely. For example, in a 1994 survey
of nine pediatric centers for hematopoietic stem cell trans-
plant in the United Kingdom, postexposure prophylaxis
consisted of VZIG alone at three centers, VZIG and acy-
clovir at one center, and acyclovir alone at the remaining
five centers.58 No two centers used the same dose of acy-
clovir. 
We have addressed six common issues in the man-
agement of VZV among recipients of hematopoietic stem
cell transplant. First, a consensus definition of VZV expo-
sure remained elusive, although a highly inclusive defini-
tion may be justified considering the potential for serious
VZV disease in this population. Second, the literature indi-
cates that recipients of hematopoietic stem cell transplant
with detectable VZV antibody are at risk for VZV infection.
Because of this apparent susceptibility, the third issue is
whether such individuals should be given postexposure
prophylaxis with VZIG. Based on our experience and our
current understanding of its efficacy, we recommend VZIG
only for postexposure prophylaxis of immunocompromised
recipients of hematopoietic stem cell transplant who are
not known to be VZV seropositive after hematopoietic stem
cell transplant. Fourth, recipients of hematopoietic stem
cell transplant should receive valacyclovir or acyclovir after
exposure unless they both are VZV seropositive and have
regained significant immunity after transplant. No consen-
sus was reached on the extent of immune restoration nec-
essary to negate the possibility of VZV reinfection. Fifth,
every effort should be made to prevent varicella in VZV-
susceptible contacts who are exposed to VZV. Finally, for
severely immunosuppressed oncology patients who have
profound T-cell immunodeficiency but are not recipients of
hematopoietic stem cell transplant, we recommend manag-
ing VZV exposures similarly to the suggested recommen-
dations for recipients of hematopoietic stem cell transplant
outlined above. 
We recognize that questions remain, opinions forged
in the absence of definitive evidence will vary markedly,
and vaccine-related exposures were not addressed.
Therefore, we hope these recommendations will stimulate
further discussion and investigation.
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